PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
MOVES-PD Clinical Trial Results - Venglustat - Cure Parkinson's
VENGLUSTAT - Emerging Insight and Market Forecast - 2030
IJMS | Free Full-Text | Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Progress towards therapies for disease modification in Parkinson's disease - The Lancet Neurology
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
venglustat | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020. - Abstract - Europe PMC
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study - ScienceDirect
SAT-112 CLINICAL TRIAL OF VENGLUSTAT, A GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITOR, IS SUPPORTED BY PRECLINICAL AND PHASE 1 STUDY
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
%20for%20Fabry%20Disease.png?md=1 "Venglustat (GZ402671) for Fabry Disease Clinical Trial 2023 | Power")
Venglustat (GZ402671) for Fabry Disease Clinical Trial 2023 | Power
Ziv Gan-Or on Twitter: "Despite being completely unclear whether glucosylceramide is relevant is PD, the plans for the trial continued as usual. Now, let's talk about some pre-clinical results, using mouse "PD
Venglustat Lowers Gb3 With No Signs of Disease Progression in Trial | Venglustat Led to Long-term Benefits in 5 of 6 Men in Phase 2 Trial | Fabry Disease News
Genes | Free Full-Text | The Genetics of Parkinson's Disease and Implications for Clinical Practice
Cells | Free Full-Text | Recent Advances in the Treatment of Genetic Forms of Parkinson’s Disease: Hype or Hope?
Novel targeted therapies for Parkinson's disease | Molecular Medicine | Full Text
Biomolecules | Free Full-Text | The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers
The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD - ScienceDirect
PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020 - IOS Press
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect
Gaucher Treatment Report
Frontiers | Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
